MedTrace Logo

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

NCT03835819 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug combination as a possible treatment for endometrial cancer.

The drugs involved in this study are:

* mirvetuximab soravtansine (IMGN853)
* pembrolizumab

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells

DRUG

IMGN853

Mirvetuximab soravtansine is an antibody-drug conjugate.

Sponsors & Collaborators

Principal Investigators

  • Rebecca Porter, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2024-06-04
Completion
2027-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03835819 on ClinicalTrials.gov